文献速递脊柱关节炎

中轴型脊柱关节炎日常临床实践中的治疗决策不止于达标治疗

Treatment decisions in axial spondyloarthritis daily clinical practice are more than treat-to-target.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

这项横断面多中心研究纳入249例临床诊断中轴型脊柱关节炎≥6个月的患者,评估医生和患者意见及BASDAI判定的缓解与低疾病活动度,并与后续治疗决策比较。结果显示医生判定的缓解患者中仅37%达到BASDAI缓解,医生认为有残留疾病活动且BASDAI>3.5的患者中60%治疗未改变,多因医生评定为低疾病活动度或合并非炎症性主诉或共病。

要点

  • 医生判定缓解的115例中仅43例(37%)达到BASDAI缓解。
  • 医生认为有残留活动且BASDAI>3.5的83例中51例(60%)治疗未改变。
  • 治疗未改变多因医生评定低疾病活动度或合并非炎症性主诉或共病。

核心结论

  • 研究表明,中轴型脊柱关节炎患者存在残留疾病活动时,医生并不总是严格遵循达标治疗原则。
  • 医生通常将低疾病活动度视为可接受而维持治疗不变。

研究设计与样本

  • 横断面多中心研究,纳入249例临床诊断中轴型脊柱关节炎≥6个月的患者。
  • 评估依据包括BASDAI(缓解<1.9、低疾病活动度<3.5)、医生意见和患者意见。
  • 问卷包括患者报告结局,患者和医生均完成关于治疗决策的问题。

主要发现

  • 249例中115例(46%)按医生意见处于缓解,其中43例(37%)按BASDAI达到缓解。
  • 医生认为有残留疾病活动且BASDAI>3.5的83例中,51例(60%)治疗未改变。
  • 治疗未改变的原因包括医生评定为低疾病活动度(15例,29%)以及低疾病活动度合并非炎症性主诉或共病(11例,25%)。
  • 回顾性达标治疗评估显示,关节炎或炎症性背痛患者治疗最常被强化,其他(非炎症性)肌肉骨骼共病患者较少被强化。

关键数值与推荐

  • BASDAI缓解定义为<1.9,低疾病活动度定义为<3.5。
  • 医生意见判定缓解者115/249(46%),其中BASDAI缓解者37%(n=43)。
  • 医生认为残留活动且BASDAI>3.5者83例,其中治疗未改变51例(60%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: 'Treat-to-target principles' are advised for axial spondyloarthritis (axSpA), although a clear target is not yet defined and targets do not always reflect inflammation. Treat-to-target use and motives for treatment choices in clinics are unknown. Therefore, we studied the presence of residual disease activity according physician's opinion, patient's opinion and composite indices and compared them to the subsequent treatment decisions. METHODS: This cross-sectional multicentre study included 249 patients with a clinical diagnosis of axSpA ≥6 months. Remission and low disease activity according to the BASDAI (<1.9 and <3.5, respectively) and physician's and patient's opinion were assessed. Questionnaires included patient-reported outcomes and patients and physicians completed questions regarding treatment decisions. RESULTS: A total of 115/249 (46%) patients were in remission according to the physician and 37% (n = 43) of these patients reached remission according to the BASDAI. In 51/83 (60%) of the patients with residual disease activity according to the physician and a BASDAI >3.5 the treatment was left unchanged, either because of low disease activity as rated by the physician [n = 15 (29%)] or because of a combination of low disease activity with non-inflammatory complaints or comorbidities [n = 11 (25%)]. Retrospective treat-to-target evaluations showed that treatments were most frequently intensified in patients with arthritis or inflammatory back pain and less often in patients with other (non-inflammatory) musculoskeletal comorbidities. CONCLUSION: This study shows that physicians do not always strictly apply treat-to-target in case of residual disease activity in axSpA. Usually, they accept low disease activity as satisfactory.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Bolt JW, Aalbers CJ, Walet L, et al. Treatment decisions in axial spondyloarthritis daily clinical practice are more than treat-to-target. Rheumatology (Oxford). 2024. PMID: 37021937. doi:10.1093/rheumatology/kead155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。